Dan S. Childs, M.D.

  1. Oncologist
  1. Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, Andrews JR, Kase AM, Riaz IB, Belge Bilgin G, Thorpe MP, Kendi AT, Johnson GB, Ravi P, Kwon ED, Childs DS. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024 Oct 30 [Epub ahead of print]
    View PubMed
  2. Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, Abdelrazek AS, Johnson DR, Johnson GB, Kwon ED, Sartor O, Kendi AT. Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. J Nucl Med. 2024 Sep 3; 65 (9):1402-1408 Epub 2024 Sept 03
    View PubMed
  3. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2024 Aug; 7 (4):877-887 Epub 2023 Dec 09
    View PubMed
  4. Ahmed ME, Mahmoud AM, Reitano G, Zeina W, Lehner K, Day CA, Riaz I, Childs DS, Orme JJ, Tuba Kendi A, Johnson GB, Jeffrey Karnes R, Kwon ED, Andrews JR. Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same? Eur Urol Open Sci. 2024 Aug; 66:38-45 Epub 2024 June 26
    View PubMed
  5. Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, Karnes RJ, Kwon ED, Childs DS, Andrews JR. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27 (2):334-338 Epub 2023 Nov 07
    View PubMed
  6. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
    View PubMed
  7. Mahmoud AM, Moustafa A, Day C, Ahmed ME, Zeina W, Marzouk UM, Basourakos S, Haloi R, Mahon M, Muniz M, Childs DS, Orme JJ, Riaz IB, Kendi AT, Stish BJ, Davis BJ, Kwon ED, Andrews JR. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers (Basel). 2024 May 30; 16 (11)
    View PubMed
  8. Mahmoud AM, Orme JJ, Childs DS, Ahmed ME, Rajkumar A, Kwon ED, Andrews JR. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience With a Rare and Aggressive Disease Progression. Clin Genitourin Cancer. 2024 Apr; 22 (2):291-294 Epub 2023 Nov 23
    View PubMed
  9. Muniz M, Childs DS, Orme JJ, Johnson GB, Sartor O. Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy. Clin Nucl Med. 2024 Apr 01; 49(4):e164-e165. Epub 2024 Feb 06.
    View PubMed
  10. Mahmoud AM, Ahmed ME, Kendi AT, Thorpe M, Johnson GB, Riaz IB, Orme JJ, Kwon ED, Andrews JR, Childs DS. Low PSA radiographic disease progression on C11-choline PET. BJUI Compass. 2024 Mar; 5 (2):319-324 Epub 2023 Oct 25
    View PubMed
  11. Dasari S, McCarthy MR, Wojcik AA, Pitel BA, Samaddar A, Tekin B, Whaley RD, Raghunathan A, Hernandez LH, Jimenez RE, Stish BJ, Thompson RH, Leibovich BC, Boorjian SA, Jeffrey Karnes R, Childs DS, Quevedo JF, Kwon ED, Pagliaro LC, Costello BA, Halling KC, Cheville JC, Kipp BR, Gupta S. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024 Feb 27. [Epub ahead of print]
    View PubMed
  12. Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2024 Feb 10 [Epub ahead of print]
    View PubMed
  13. Lewis AR, Choong GM, Cathcart-Rake E, Florez N, Durani U, Yadav S, Fuentes H, Sorensen K, Childs DS, Saliba A, Paludo J, Hobday TJ. Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat. J Cancer Educ. 2024 Feb; 39 (1):58-64 Epub 2023 Oct 17
    View PubMed
  14. Mahmoud AM, Childs DS, Ahmed ME, Tuba Kendi A, Johnson GB, Orme JJ, Stish BJ, Phillips RM, Park SS, Davis BJ, Andrews JR, Kwon ED. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. Prostate. 2024 Feb; 84 (3):237-244 Epub 2023 Oct 29
    View PubMed
  15. Childs DS, Novotny PJ, Marell PS, Ruddy KJ, Loprinzi CL. Hot flash clinical trial baseline measurements: how long is needed? BMJ Support Palliat Care. 2024 Jan 8; 13 (e3):e1110-e1116 Epub 2024 Jan 08
    View PubMed
  16. Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024; 14(6):2367-2378. Epub 2024 Mar 25.
    View PubMed
  17. Belge Bilgin G, Bilgin C, Childs DS, Orme JJ, Burkett BJ, Packard AT, Johnson DR, Thorpe MP, Riaz IB, Halfdanarson TR, Johnson GB, Sartor O, Kendi AT. Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer (177)Lu-PSMA-617 therapy. Front Oncol. 2024; 14:1386718 Epub 2024 July 12
    View PubMed
  18. Mahmoud, Gao, Ahmed, Orme, Rincón M, Harmsen, Johnson, Cassivi, Kwon, Phillips, Andrews, Childs D. Metastasis-directed therapy for metachronous lung metastases in prostate cancer JU Open Plus. 2023.
  19. Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023 May 1; 9 (5):635-645
    View PubMed
  20. Kochan DC, Novotny PJ, Cathcart-Rake EJ, Orme JJ, Tevaarwerk AJ, Ruddy KJ, Childs DS. An evaluation of the effect of lithium on taxane-induced neuropathy. Support Care Cancer. 2023 Apr 25; 31(5):299.
    View PubMed
  21. Childs DS, Helfinstine DA Jr, Sangaralingham L, Orme JJ, O'Sullivan CC, Loprinzi CL, Ruddy KJ. Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy. JCO Oncol Pract. 2022 Dec; 18(12):e1953-e1960. Epub 2022 Oct 31.
    View PubMed
  22. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):684-692 Epub 2022 July 22
    View PubMed
  23. Santivasi WL, Childs DS, Wu KL, Partain DK, Litzow MR, LeBlanc TW, Strand JJ. Perceptions of Hematology Among Palliative Care Physicians: Results of a Nationwide Survey. J Pain Symptom Manage. 2021 Nov; 62 (5):949-959 Epub 2021 Apr 29
    View PubMed
  24. Childs DS, Quevedo JF, Costello BA, Pagliaro LC. Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. Anticancer Drugs. 2021 Oct 1; 32 (9):986-990
    View PubMed
  25. Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021 Sep; 99:102241 Epub 2021 June 09
    View PubMed
  26. Childs DS, Le-Rademacher JG, McMurray R, Bendel M, O'Neill C, Smith TJ, Loprinzi CL. Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis. J Pain Symptom Manage. 2021 Jun; 61 (6):1247-1253 Epub 2020 Nov 27
    View PubMed
  27. Childs DS, Yoon HH, Eiring RA, Jin Z, Jochum JA, Pitot HC, Jatoi A. Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. Support Care Cancer. 2021 Feb; 29 (2):733-739 Epub 2020 May 24
    View PubMed
  28. Childs DS, Looker S, Le-Rademacher J, Ridgeway JL, Breitkopf CR, Jatoi A. What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. Support Care Cancer. 2019 Jan; 27 (1):249-255 Epub 2018 June 25
    View PubMed
  29. Childs DS, Jatoi A. A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. Ann Palliat Med. 2019 Jan; 8 (1):50-58 Epub 2018 May 24
    View PubMed
  30. Bartlett DJ, Childs DS, Breitkopf CR, Grudem ME, Mitchell JL, Looker SA, Ridgeway JL, Lee JL, Butterfield JH, Weroha SJ, Jatoi A. Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. Am J Hosp Palliat Care. 2018 Nov; 35 (11):1384-1389 Epub 2018 May 03
    View PubMed
  31. Aseem O, Childs DS, Loftus CG. Diffuse Small Intestine Erosions and Ulcers in an Immunocompromised Host. Gastroenterology. 2018 Apr; 154 (5):1241-1243 Epub 2017 July 13
    View PubMed
  32. Childs DS, Tracy SI, Thanarajasingam U. 46-Year-Old Man With Lower Back Pain. Mayo Clin Proc. 2017 Oct; 92 (10):e133-e137 Epub 2017 Aug 24
    View PubMed
  33. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  34. Day JJ, Childs D, Guzman-Karlsson MC, Kibe M, Moulden J, Song E, Tahir A, Sweatt JD. DNA methylation regulates associative reward learning. Nat Neurosci. 2013 Oct; 16 (10):1445-52 Epub 2013 Aug 25
    View PubMed
  35. Olsen CM, Childs DS, Stanwood GD, Winder DG. Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5). PLoS One. 2010 Nov 30; 5 (11):e15085
    View PubMed